Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from …
Y Han, T Zhang, H Chen, X Yang - Critical Reviews in Oncology …, 2022 - Elsevier
Understanding the burden of mesothelioma with the contribution of occupational asbestos
exposure globally provides essential foundations for cancer control, policy decisions and …
exposure globally provides essential foundations for cancer control, policy decisions and …
Updates in Management of Malignant Pleural Mesothelioma
A John, H O'Sullivan, S Popat - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Malignant pleural mesothelioma (MPM) is an aggressive asbestos-
associated thoracic malignancy that is usually incurable. As demonstrated in the landmark …
associated thoracic malignancy that is usually incurable. As demonstrated in the landmark …
H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth
The role of glucose-6-phosphate dehydrogenase (G6PD) in human cancer is incompletely
understood. In a metabolite screening, we observed that inhibition of H3K9 methylation …
understood. In a metabolite screening, we observed that inhibition of H3K9 methylation …
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition
S Paternot, E Raspé, C Meiller, M Tarabichi… - Molecular …, 2024 - Wiley Online Library
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic
options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines …
options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines …
Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma
DP Anobile, G Montenovo, C Pecoraro… - Expert Review of …, 2022 - Taylor & Francis
ABSTRACT Introduction Malignant mesothelioma (MMe) is an aggressive rare cancer of the
mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at …
mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at …
Patient-level omics data analysis identifies gene-specific survival associations for a PD-1/PD-L1 network in pleural mesothelioma
GM O'Connor, EY Bakker - BioMedInformatics, 2022 - mdpi.com
Immune checkpoint blockade targeting PDCD1 (PD-1) or CD274 (PD-L1) has demonstrated
efficacy and interest across multiple cancers. However, the exact determinants of the …
efficacy and interest across multiple cancers. However, the exact determinants of the …
Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights
RL Castro, ÁF Martín, AM Del Valle, TG Peña… - Open Respiratory …, 2024 - Elsevier
MPM stands as a rare malignancy necessitating improved therapeutic strategies due to its
limited treatment choices and unfavorable prognosis. The advent of immune checkpoint …
limited treatment choices and unfavorable prognosis. The advent of immune checkpoint …
[PDF][PDF] Biomarkers in mesothelioma and non-small cell lung cancer-Investigation of cytological specimens with correlation to histology
MSI Mansour - 2024 - portal.research.lu.se
Pleural mesothelioma (PM) and non-small cell lung cancer (NSCLC) are two highly lethal
pleuropulmonary malignancies where ancillary analyses are needed for accurate diagnosis …
pleuropulmonary malignancies where ancillary analyses are needed for accurate diagnosis …
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition
S Paternot, E Raspé, C Meiller, M Tarabichi, JB Assié… - BioRxiv, 2022 - biorxiv.org
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic
options. In this study, we evaluated the impact of CDK4/6 inhibition by palbociclib in a panel …
options. In this study, we evaluated the impact of CDK4/6 inhibition by palbociclib in a panel …